<code id='845545EE0B'></code><style id='845545EE0B'></style>
    • <acronym id='845545EE0B'></acronym>
      <center id='845545EE0B'><center id='845545EE0B'><tfoot id='845545EE0B'></tfoot></center><abbr id='845545EE0B'><dir id='845545EE0B'><tfoot id='845545EE0B'></tfoot><noframes id='845545EE0B'>

    • <optgroup id='845545EE0B'><strike id='845545EE0B'><sup id='845545EE0B'></sup></strike><code id='845545EE0B'></code></optgroup>
        1. <b id='845545EE0B'><label id='845545EE0B'><select id='845545EE0B'><dt id='845545EE0B'><span id='845545EE0B'></span></dt></select></label></b><u id='845545EE0B'></u>
          <i id='845545EE0B'><strike id='845545EE0B'><tt id='845545EE0B'><pre id='845545EE0B'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:44
          The logo of Department of Justice on a podium — coverage from STAT
          BRENDAN SMIALOWSKI/AFP via Getty Images

          Community Health Systems is facing a new federal probe into its hospital billing practices more than four years after the hospital chain settled separate allegations of fraudulent overbilling.

          CHS, a national system of 71 rural and suburban hospitals, said this week it received a civil investigative demand from the Department of Justice on Jan. 11. Federal investigators asked CHS to hand over documents that covered “practices and procedures related to utilization review, inpatient admissions, and inpatient dialysis at our hospitals.”

          advertisement

          The DOJ initiates these investigations into health care companies when it believes there could be a False Claims Act case, but has not initiated or joined any lawsuits yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          The lessons of Aduhelm, an Alzheimer's drug that was not to be
          The lessons of Aduhelm, an Alzheimer's drug that was not to be

          StevenSenn/APAduhelm,apioneeringtreatmentforAlzheimer’sdiseasethatcollapsedundercorporatemistakesand

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          WuXi out of biotech trade group, U.S. and China relations to blame

          AdobeWASHINGTON—TheBiotechnologyInnovationOrganization,anindustrytradegroup,iscuttingtieswithChinese